Full Text (PDF)
Original Article

Role of HER-2/Neu Expression in Premalignant and Malignant Lesions of Uterine Cervix

Rajesh Kumar Rai, Professor, Department of Pathology, B.R.D. Medical College, Gorakhpur, Uttar Pradesh 273013, India. , Shaila Kumari Mitra1 , Rajesh Kumar Rai2 , Kiriti Kanaujiya3 , Manjari Rao4

Author Information

Licence:




Indian Journal of Pathology: Research and Practice 7(11):p 1171-1175, November 2018. | DOI: http://dx.doi.org/10.21088/ijprp.2278.148X.71118.11

How Cite This Article:


Timeline

Received : N/A         Accepted : N/A          Published : N/A

Abstract

Background: HER-2/neu is a gene localized on chromosome 17q21 which encodes a growth factor receptor like molecule with tyrosine kinase activity and is known to encode a transmembrane glycoprotein. Aim: To study the expression of HER2/neu in benign and malignant lesions of cervix. Material and Methods: The present study was conducted on 100 cases of resected cervical tissue specimen suspected to have neoplastic lesions and hysterectomy specimen already diagnosed as carcinoma on cytology for a period of 12 months (September 2018 to August 2019). Results: Majority of benign cases were negative for HER-2/neu except few cases and positivity was higher in malignant than premalignant. Positivity was also higher in adenocarcinoma as compared to squamous cell carcinoma. Conclusion: HER-2/neu serves as a biological marker to identify high risk subgroups and can be useful as target for new treatment modalities.

 


References

No records found.


About this article


Cite this article


Licence:




Received Accepted Published
N/A N/A N/A

DOI: http://dx.doi.org/10.21088/ijprp.2278.148X.71118.11

Keywords

Her-2 /neu; Epithelial Cells; Cervical Cancer.   

Article Level Metrics

Last Updated

Sunday 12 July 2026, 13:53:18 (IST)


2018

Accesses

3
434
00

Citations


NA
NA
NA

Download citation


Article Keywords


Keyword Highlighting

Highlight selected keywords in the article text.


Timeline


Received N/A
Accepted N/A
Published N/A

licence



Access this article



Share